RAPPAPORT ANDREW 4

What Happened Andrew Rappaport, a director of Olema Pharmaceuticals, was granted a derivative award on June 18, 2026 covering 29,500 shares (reported as a stock option) with an exercise/price reported as $0.00. The grant is recorded as an award/acquisition (code A) and has no immediate cash value reported.

Key Details

• Transaction date: 2026-06-18; filing date (Form 4): 2026-06-23 (filed after the typical 2-business-day deadline).
• Securities: 29,500 derivative shares (stock option) at $0.00 per share.
• Shares owned after the transaction: Not disclosed in the supplied filing.
• Vesting: The shares underlying the option vest in 12 equal monthly installments starting June 18, 2026; any unvested portion vests in full on the issuer's next annual meeting if not already vested, subject to continuous service. (See footnote.)
• No indication in the filing that shares were immediately sold, withheld for tax, or part of a 10b5-1 plan.

Context This is a grant of a stock option award to a company director. Such awards are common as compensation and do not necessarily reflect immediate buying or selling sentiment. The grant has a monthly vesting schedule and an acceleration clause tied to the next annual meeting; because it was reported several days after the transaction date, the filing appears to be late relative to the usual two-business-day Form 4 deadline.